CD8A and glioma: The MG-Act cell population was identified in the WT GEMM MAPK-driven, low-grade glioma preclinical model (Figure 5, K and L, and Supplemental Tables 6 and 7), which became more abundant with anti-TIM3 treatment alongside other effector cell populations including CD8+ cytotoxic T cells (Figure 5M).